Dossier assessment
Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
adult patients with multiple myeloma who have received at least one previous treatment
added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-03-16 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A22-100
- Commission
- Commission awarded on 29.09.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Selinexor (multiple myeloma, fifth line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100
Status: Commission completed